Perspectives on designs of antiandrogens for prostate cancer

Expert Opinion on Drug Discovery

Volumn 2, Issue 10, 2007, Pages 1341-1355

  Estébanez Perpiñá, Eva ^a   Jouravel, Natalia ^a   Fletterick, Robert J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AF2; Androgen receptor; Androgen independent prostate cancel; Antiandrogens; Co activator binding pocket; Co activators; Ligand binding pocket; Surface inhibitors

Indexed keywords

11BETA (4 FLUOROPHENYL) 17BETA HYDROXY 17ALPHA (1 VINYL)ESTRA 4,9 DIEN 3 ONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROXYFLUTAMIDE; MIFEPRISTONE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; SPIRONOLACTONE; SUMO 1 PROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING AFFINITY; CHEMICAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HYDROPHOBICITY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; RECEPTOR BLOCKING; REVIEW; TRANSCRIPTION REGULATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 35348915495     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.10.1341     Document Type: Review

References (100)

1. LUBAHN D, JOSEPH DR, SULLIVAN PM, WILLARD HF, FRENCH FS, WILSON EM: Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science (1988) 240:327-330.
2. LEE HJ, CHANG C: Recent advances in androgen receptor action. Cell Mol. Life Sci. (2003) 60:1613-1622.
3. TILLEY WD, MARCELLI M, WILSON JD, MCPHAUL MJ: Characterization and expression of a cDNA encoding the human androgen receptor. Proc. Natl. Acad. Sci. USA (1989) 86:327-331.
4. JENSTER G, VAN DER KORPUT HA, VAN VROONHOVEN C, VAN DER KWAST TH, TRAPMAN J, BRINKMANN AO: Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. (1991) 5:1396-1404.
5. JENSTER G, VAN DER KORPUT HA, TRAPMAN J, BRINKMANN AO: Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. (1995) 270:7341-7346.
6. PARNES HL, THOMPSON IM, FORD LG: Prevention of hormone-related cancers: prostate cancer. J. Clin. Oncol. (2005) 23:368-377.
7. SINGH P, UZGARE A, LITVINOV I, DENMEADE SR, ISAACS JT: Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr. Relat. Cancer (2006) 13:653-666.
8. MCKENNA NJ, NAWAZ Z, TSAI SY, TSAI MJ, O'MALLEY BW. Distinct steady-state nuclear receptor coregulator complexes exist in vivo. Proc. Natl. Acad. Sci. USA (1998) 95:11697-11702.
9. PRESCOTT J, COETZEE GA. Molecular chaperones throughout the Ue cycle of the androgen receptor. Cancer Lett. (2006) 231:12-19.
10. CARDOZO CP, MICHAUD C, OST MC et al.: C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch. Biochem. Biophys. (2003) 410:134-140.
11. FENG W, RIBEIRO RC, WAGNER RL et al.: Hormone-dependent coactivator binding to a hydrophobic deh on nuclear receptors. Science (1998) 280:1747-1749.
12. ARANDA A, PASCUAL A. Nuclear hormone receptors and gene expression. Physiol. Rev. (2001) 81:1269-1304.
13. BOURGUET W, GERMAIN P, GRONEMEYER H: Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. (2000) 21:381-388.
14. MORAS D, GRONEMEYER H: The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. (1998) 10:384-391.
15. WURTZ JM, BOURGUET W, RENAUD JP et al.: A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. (1996) 3:206.
16. NICHOLS M, RIENTJES JM, STEWART AF: Different positioning of the ligand-binding domain hefix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J. (1998) 17:765-773.
17. DARIMONT BD: Finding specificity within a conserved interaction site. Chem. Biol. (2003) 10:675-676.
18. BURD CJ, MOREY LM, KNUDSEN KE: Androgen receptor corepressors and prostate cancer. Endocr. Relat. Cancer (2006) 13:979-994.
19. MARCELLI M, STENOIEN DL, SZAFRAN AT et al.: Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J. Cell Biochem. (2006) 98:770-788.
20. TYAGI RK, LAVROVSKY Y, AHN SC, SONG CS, CHATTERJEE B, ROY AK: Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol. Endocrinol. (2000) 14:1162-1174.
21. POUKKA H, KARVONEN U, YOSHIKAWA N, TANAKA H, PALVIMO JJ, JANNE OA: The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J. Cell Sci. (2000) 113:2991-3001.
22. WHITAKER HC, HANRAHAN S, TOTTY N et al.: Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic an tiandrogens. Clin. Cancer Res. (2004) 10:7392-7401.
23. BEVAN CL, HOARE S, CLAESSENS F, HEERY DM, PARKER MG: The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol. Cell Biol. (1999) 19:8383-8392.
24. ZHOU ZX, HE B, HALL SH, WILSON EM, FRENCH FS: Domain interactions between coregulator ARA(70) and the androgen receptor (AR). Mol. Endocrinol. (2002) 16:287-300.
25. MCKENNA N, XU J, NAWAZ Z, TSAI SY, TSAI MJ, O'MALLEY BW: Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J. Steroid Biochem. Mol. Biol. (1999) 69:3-12.
26. LONARD DM, O'MALLEY BW: The expanding cosmos of nuclear receptor coactivators. Cell(2006) 125:411-414.
27. GLAESER M, FLOETOTTO T, HANSTEIN B, BECKMANN MW, NIEDERACHER D: Gene amplification and expression of die steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm. Metab. Res. (2001) 33:121-126.
28. CHMELAR R, BUCHANAN G, NEED EF, TILLEY W, GREENBERG NM: Androgen receptor coregulators and their involvement in the development and progression of Prostate cancer. Int J. Cancer (2007) 120:719-733.
29. LINJA MJ, PORKKA KP, KANG Z et al.: Expression of androgen receptor coregulators; in prostate cancer. Clin. Cancer Res. (2004) 10:1032-1040.
30. SHANG Y, MYERS M, BROWN M: Formation of the androgen receptor transcription complex. Mol. Cell (2002) 9:601-610.
31. HE B, LEE LW, MINGES JT, WILSON EM: Dependence of selective gene activation on die androgen receptor NH2- and COOH-terminal interaction. J. Biol. Chem. (2002) 277:25631-25639.
32. LI J, FU J, TOUMAZOU C, YOON HG, WONG J: A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol. Endocrinol. (2006) 20:776-785.
33. FAUS H, HAENDLER B: Post-translational modifications of steroid receptors. Biomed Pharmacother. (2006) 60:520-528.
34. WONG HY, BURGHOORN JA, VAN LEEUWEN M et al.: Phosphorylation of androgen receptor isoforms. Biochem. J. (2004) 383:267-276.
35. THOMAS M, DADGAR N, APHALE A et al.: Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J. Biol. Chem. (2004) 279:8389-8395.
36. POUKKA H, KARVONEN U, JANNE OA, PALVIMO JJ: Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. USA (2000) 97:14145-14150.
37. TAPLIN M: Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat. Clin. Pract. Oncol (2007) 4:236-244.
38. TUREK-PLEWA J, TRZECIAK WH: Gene symbol: AR. Disease: androgen insensitivity syndrome. Hum. Genet. (2006) 119:361.
39. FISCHBECK KH: Kennedy disease. J. Inherit Metab. Dis. (1997) 20:152-158.
40. BRINKMANN AO, JENSTER G, RIS-STALPERS C et al.: Androgen receptor mutations. J. Steroid Biochem. Mol. Biol. (1995) 53:443-448.
41. MCPHAUL MJ: Molecular defects of the androgen receptor. Recent Prog. Horm. Res. (2002) 57:181-194.
42. BUCHANAN G, GREENBERG NM, SCHER HI, HARRIS JM, MARSHALL VR, TILLEY WD: Collocation of androgen receptor gene mutations in prostate cancer. Clin. Cancer Res. (2001) 7:1273-1281.
43. HAN G, BUCHANAN G, ITTMANN M et al.: Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl. Acad. Sci. USA (2005) 102:1151-1156.
44. LI M, MIWA S, KOBAYASHI Y et al.: Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann. Neurol. (1998) 44:249-254.
45. BRINKMANN AO: Molecular basis of androgen insensitivity. Mol. Cell Endocrinol. (2001) 179:105-109.
46. BOSINSKI HA: Psychosexual aspects of intersex syndromes. Urologe A. (2006) 45:981-991.
47. LEDIG S, JAKUBICZKA S, NEULEN J et al.: Novel and recurrent mutations in patients with androgen insensitivity syndromes. Horm. Res. (2005) 63:263-269.
48. YONG EL, TUT TG, GHADESSY FJ, PRINS G, RATNAM SS: Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain (1998) 137(1):41-50.
49. ONG YC, KOLATKAR PR, YONG EL: Androgen receptor mutations causing human androgen insensitivity syndromes show a key role of residue M807 in helix 8-helix 10 interactions and in receptor ligand-binding domain stability. Mol. Hum. Reprod. (2002) 8:101-108.
50. JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. CA Cancer J. Clin. (2007) 57:43-66.
51. GREENE KL, COWAN JE, COOPERBERG MR, MENG MV, DUCHANE J, CARROLL PR, CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR (CAPSURE) INVESTIGATORS: Who is the average patient presenting with prostate cancer? Urology (2005) 66:76-82.
52. TRUE L, COLEMAN I, HAWLEY S et al.: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc. Natl. Acad. Sci. USA (2006) 103:10991-10996.
53. BRAWER MK- Prostatic intraepithelial neoplasia: an overview. Rev. Urol. (2005) 7:S11-S18.
54. STENMAN UH, LEINONEN J, ZHANG WM, FINNE P, WU P: The clinical importance of free prostate-specific antigen (PSA). Curr. Opin. Urol. (1998) 8:393-399.
55. CULIG Z, BARTSCH G: Androgen axis in prostate cancer. J. Cell Biochem. (2006) 99:373-381.
56. CRAFT N, SAWYERS CL: Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metast. Rev. (1998-1999) 17:421-427.
57. CULIG Z, KLOCKER H, BARTSCH G, HOBISCH A. Androgen receptors in prostate cancer. Endocr. Relat. Cancer (2002) 9:155-170.
58. CHEN C, WELSBIE DS, TRAN C et al.: Molecular determinants of resistance to antiandrogen therapy. Nat. Med. (2004) 10:33-39.
59. SCHER H, SAWYERS CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. (2005) 23:8253-8261.
60. AGOULNIK IU, WEIGEL NL: Androgen receptor action in hormone-dependent and recurrent prostate cancer. J. Cell. Biochem. (2006) 99:362-372.
61. GREGORY CW, HE B, JOHNSON RT et al.: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. (2001) 61:4315-4319.
62. PAGE ST, LIN DW, MOSTAGHEL EA et al.: Persistent intraprostatic androgen concentrations after medical castration in healthy men. J. Clin. Endocrinol. Metab. (2006) 91:3850-3856.
63. EDWARDS J, KRISHNA NS, GRIGOR KM, BARTLETT JM: Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer (2003) 89:552-556.
64. CHEN S, XU Y, YUAN Y, BUBLEY GJ, BALK SP: Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc. Natl. Acad. Sci. USA (2006) 103:15969-15974.
65. SAPORITA AJ, ALI J, WANG Z: The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate (2007) 67:509-520.
66. SHAFFER PL, JIVAN A, DOLLINS DE, CLAESSENS F, GEWIRTH DT: Structural basis of androgen receptor binding to selective androgen response elements. Proc. Natl. Acad. Sci. USA (2004) 101:4758-4763.
67. MATIAS PM, DONNER P COELHO R et al.: Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. (2000) 275:26164-26171.
68. SACK A KISH KF, WANG C et al.: Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydratestosterone. Proc. Natl. Acad. Sci. USA (2001) 98:4904-4909.
69. PEREIRA DE JESUS-TRAN K, COTE PL et al.: Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci. (2006) 15:987-999.
70. MATIAS PM, CARRONDO MA, COELHO R et al.: Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J. Med. Chem. (2002) 45:1439-1446.
71. TILLEY WD, BUCHANAN G, HICKEY TE, BENTEL JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. (1996) 2:277-285.
72. FENTON MA, SHUSTER TD, FERTIG AM et al.: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. (1997) 3:1383-1388.
73. HARA T, MIYAZAKI J, ARAKI H et al.: Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. (2003) 63:149-153.
74. BOHL CE, MILLER DD, CHEN J, BELL CE, DALTON JT: Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J. Biol. Chem. (2005) 280:37747-37754.
75. BOHL CE, GAO W, MILLER DD, BELL CE, DALTON JT: Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. USA (2005) 102:6201-6206.
76. BRINKMANN A, TRAPMAN J: Prostate cancer schemes for androgen escape. Nat. Med. (2000) 6:628-629.
77. SCHRIJVERS D: Androgen-independent prostate cancer. Rec. Res. Cancer Res. (2007) 175:239-249.
78. MCGINLEY P, KOH JT- Circumventing anti-androgen resistance by molecular design. J. Am. Chem. Soc. (2007) 129:3822-3823.
79. CADILLA R, TURNBULL P: Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr. Top. Med. Chem. (2006) 6:245-270.
80. ESTEBANEZ-PERPINA E, MOORE JM, MAR E et al.: The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J. Biol. Chem. (2005) 280:8060-8068.
81. GAO V, DALTON JT: Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov. Today (2007) 12:241-248.
82. MAHAJAN D, LONDON S: Mifepristone (RU486): a review. Fertil. Steril. (1997) 68:967-976.
83. NIRDE P, TEROUANNE B, GALLAIS N, SULTAN C, AUZOU G: Antimineralocorticoid 11β-substituted spirolactones exhibit androgen receptor agonistic activity: a structure function study. Mol. Pharmacol. (2001) 59:1307-1313.
84. PIKE A, BRZOZOWSKI AM, WALTON J et al.: Structural insights into the mode of action of a pure antiestrogen. Structure (2001) 9:145-153.
85. HASHIMOTO Y, MIYACHI H: Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis. iBioorg. Med. Chem. (2005) 13:5080-5093.
86. HODGSON M, ASTAPOVA I, CHENG S et al.: The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J. Biol. Chem. (2005) 280:6511-6519.
87. LIN M, KAWACHI MH, STALLCUP MR, GRUNBERG SM, LIN FF: Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-nonsteroid derivative agent, mifepristone. Prostate (1995) 26:194-204.
88. HAMILTON G, BACKES BJ: Synthesis of C-11 modified mifepristone analog libraries. Mol. Divers (2007) 11:107-111.
89. HANDRATTA V, VASAITIS TS, NJAR VC et al.: Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. (2005) 48:2972-2984.
90. MUDDANA S, PRICE AM, MACBRIDE MM, PETERSON BR: 11β-alkyl-d9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor. J. Med. Chem. (2004) 47:4985-4988.
91. BORNGRAEBER S, BUDNY MJ, CHIELLINI G et al.: Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Natl. Acad. Sci. USA (2003) 100:15358-15363.
92. CHANG C, MCDONNELL DP: Androgen-receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol. Sci. (2005) 26:225-228.
93. HUR E, PFAFF Sj, STURGIS PE, HANNE G, BUEHRER BM, FLETTERICK RJ: Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS (2004) 2:363.
94. CHANG CY, ABDO J, HARTNEY T, MCDONNELL DP: Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol. Endocrinol. (2005) 19:2478-2490.
95. QUAYLE SN, MAWJI NR, WANG J, SADAR MD: Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl. Acad. Sci. USA (2007) 104:1331.
96. ARNOLD LA, ESTEBANEZ-PERPINA E, TOGASHI M et al.: Discovery of small molecule inhibitors of the interaction of thyroid hormone receptor with transcriptional coregulators. J. Biol. Chem. (2005) 290:43048-43055.
97. ARNOLD LA, ESTEBANEZ-PERPINA E, TOGASHI M et al.: A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Sci. STKE (2006) 341:13.
98. HE B, GAMPE RT Jr, KOLE AJ et al.: Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol. Cell (2004) 16(3):425-438.
99. SALVATI ME, BALOG A, SHAN W et al.: Structure based approach to the design of bicydic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15:271-276.
100. ESTÉBANEZ-PERPIÑÁ E, ARNOLD LA, NGUYEN P et al.: A surface on the androgen receptor that allosterically regulates coactivator binding. Proc. Natl. Acad. Sci. USA (2007) (In Press).